HER2 analysis in circulating tumor cells (CTCs) may have clinical significance for HER2-targeted therapy as HER2-positive CTCs and disseminated tumor cells can be detected in patients with HER2-negative primary tumors who currently do not have access to HER2-targeted therapy. In this study, we performed quantitative analysis by confocal microscopy assay for evaluation of HER2 expression in individual tumor cells. HER2 testing by confocal microscopy assay exhibited high concordance with results of real-time PCR, Western blot analysis and FISH analysis. We found that there was a significant positive correlation between HER2 overexpression and gene amplification in individual CTCs, which provided validation of confocal microscopy assay for HER...
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment tar...
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment tar...
Background HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic se...
Circulating tumor cells (CTC) can provide the basis for a real-time liquid biopsy and may guide the ...
International audienceThere is a growing body of evidence that HER2 status can change during disease...
BACKGROUND:Personalized targeted treatment in metastatic breast cancer relies on accurate assessment...
International audienceBiocharacterization of circulating tumor cells (CTCs) in the peripheral blood ...
Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, le...
Circulating Tumor Cells (CTCs) detection and phenotyping are currently evaluated in Breast Cancer (B...
International audienceBACKGROUND: Tumor-derived extracellular vesicles (tdEVs) and circulating tumor...
PURPOSE: Circulating Tumor Cells (CTCs) detection and phenotyping are currently evaluated in Breast ...
HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection proces...
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment tar...
Background Personalized targeted treatment in metastatic breast cancer relies on accurate assessmen...
BACKGROUND: Circulating tumour cells (CTCs) offer a non-invasive approach to obtain and characteris...
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment tar...
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment tar...
Background HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic se...
Circulating tumor cells (CTC) can provide the basis for a real-time liquid biopsy and may guide the ...
International audienceThere is a growing body of evidence that HER2 status can change during disease...
BACKGROUND:Personalized targeted treatment in metastatic breast cancer relies on accurate assessment...
International audienceBiocharacterization of circulating tumor cells (CTCs) in the peripheral blood ...
Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, le...
Circulating Tumor Cells (CTCs) detection and phenotyping are currently evaluated in Breast Cancer (B...
International audienceBACKGROUND: Tumor-derived extracellular vesicles (tdEVs) and circulating tumor...
PURPOSE: Circulating Tumor Cells (CTCs) detection and phenotyping are currently evaluated in Breast ...
HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection proces...
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment tar...
Background Personalized targeted treatment in metastatic breast cancer relies on accurate assessmen...
BACKGROUND: Circulating tumour cells (CTCs) offer a non-invasive approach to obtain and characteris...
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment tar...
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment tar...
Background HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic se...